STOCK TITAN

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.

Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.

Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.

Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.

Rhea-AI Summary
Sight Sciences announces TearCare SAHARA Six Month RCT Results reception
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
-
Rhea-AI Summary
Sight Sciences announces positive results from the SAHARA trial, demonstrating the superiority of TearCare technology over Restasis eyedrops for the treatment of dry eye disease. TearCare showed statistically significant improvements in tear break up time and other objective signs of dry eye compared to Restasis. Both treatments delivered comparable improvements in patient-reported outcomes. TearCare offers an efficacious and durable interventional dry eye treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary
Sight Sciences announces results of a large-scale study comparing MIGS technologies for glaucoma patients. TCOR procedure using OMNI Surgical System shows significant reduction in IOP and medication usage. OMNI technology delivers clinically meaningful and durable results. Independent data from the IRIS Registry informs surgeons' decision-making. Sight Sciences aims to elevate the standard of care with its technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
Rhea-AI Summary
Sight Sciences updates revenue guidance for Q3 2023 to $19.0M-$20.0M, expects decrease in new account additions and utilization due to proposed LCDs. Revenue from Dry Eye segment to be slightly down sequentially. Full year 2023 revenue guidance updated to $80.0M-$82.0M, representing 12%-15% growth compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.62%
Tags
none
-
Rhea-AI Summary
Sight Sciences appoints Matthew Link as Chief Commercial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.62%
Tags
management
-
Rhea-AI Summary
Sight Sciences to present at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
-
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) will report Q2 2023 financial results on August 3. The company focuses on developing eyecare technology to improve patients' lives. Investors can access a live webcast of the conference call on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.06%
Tags
conferences earnings
-
Rhea-AI Summary
Sight Sciences, Inc. announces six-month results from the SAHARA trial, demonstrating the superiority of interventional eyelid procedures enabled by TearCare over Restasis eye drops for the treatment of dry eye disease. The trial achieved its primary endpoint, showing statistically significant improvements in tear break up time (TBUT) and non-inferiority in Ocular Surface Disease Index (OSDI). TearCare patients experienced improvement in key signs and symptoms of dry eye. The results support the clinical superiority of TearCare technology and highlight the potential to change how meibomian gland disease and dry eye are treated in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

SGHT Stock Data

136.54M
40.43M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK